TACE联合门静脉支架治疗伴门静脉癌栓原发性肝癌的效果分析

目的 研究肝动脉化疗栓筛(TACE)联合门静脉支架植入术治疗伴门静脉癌栓原发性肝癌的效果.方法 在遵循随机对照原则和入选标准的基础上,选取2012年7月至2015年1月确诊为原发性肝癌伴门静脉癌栓15例患者为观察组,选取2010年1月至2012年6月于我科确诊为原发性肝癌伴门静脉癌栓但仅接受TACE治疗的15例患者为对照组,而观察组则接受肝动脉化疗栓筛(TACE)联合门静脉支架植入术治疗.对比两组患者治疗前后肝功能主要指标和并发症情况,并随访两组患者的生存时间.结果 与治疗前比较,两组患者治疗后肝功能主要指标水平差异明显,均具有统计学意义(P<0.05),且观察组肝功能主要指标改善情况显著优于对照组,差异均具有统计学意义(P<0.05).与对照组比较,观察组出现肝性腹腔积液、肝性脑病、严重感染及肺转移患者例数明显减少,且差异均具有统计学意义(P<0.05).与对照组比较,观察组总生存时间明显延长,且差异均具有统计学意义(P<0.05).结论 肝动脉化疗栓筛(TACE)联合门静脉支架植入术不仅可降低患者并发症的发生率,同时还可有效改善中晚期患者的肝功能,其在延长患者生存时间上也有显著的效果,值得临床推广运用.

Effect Analysis of TACE Combined with Portal Vein Stent Implantation Treating Primary Liver Cancer with Portal Vein Tumor Thrombus

Objective To explore the effect analysis of TACE combined with portal vein stent implantation treating the patients who were primary liver cancer with portal vein tumor thrombus.Methods Based on the principle of random control and inclusion criteria,we selected 15 patients who were were diagnosed as primary hepatocellular carcinoma with portal vein tumor thrombosis in our department as observation group,15 patients who were were diagnosed as primary hepatocellular carcinoma with portal vein tumor thrombosis and were not given TACE in our department was the control group,the observation group were given TACE combined with portal vein stent implantation.Compared the complications and the liver function indexes in the 2 groups,in addition,the survival time was followed in the 2 groups.Results In comparison with before treatment,the changes in main indexes of liver function were significant in the 2 groups after treatment,the differences were statistical significant(P<0.05),and the main indexes of liver function in the observation group were much better than the control group,the differences were statistically significant(P<0.05).Compared with the control group,the patients who were with hepatic ascites,hepatic encephalopathy,severe infection and pulmonary metastasis were significantly reduced in the observation group,and the difference was statistically significant(P<0.05).Compared with the control group,the total survival time of the observation group was significantly prolonged,and the difference was statistically significant(P<0.05).Conclusion TACE combined with portal vein stent implantation treating can reduce the incidence rate of complication,and improve liver function of patients with advanced effectively,it also can prolong the survival time of patients,it is worthy of clinical application.